Alzheimer’s Studies and Trials

Filters
Filters
Enrollment Status
Study Type
Age Range
Cognitive Status
Show (2)
Cancel
Reset Filters
Actively Enrolling
, ,

Synaptic Therapy Alzheimer’s Research Trial

This study is investigating whether CT1812, a novel and promising therapeutic candidate can halt or slow the process of Alzheimer’s disease. The START Study is a nationwide clinical trial and will enroll approximately 540 individuals. Participants aged 50 to 85 with mild cognitive impairment (MCI) due to Alzheimer’s disease, or mild Alzheimer’s disease who have elevated amyloid in the brain (as measured by PET or CSF), are sought. Participants will be randomized to receive CT1812 or placebo for 18 months. In addition to a battery of cognitive measures, the study will use a variety of biomarkers to evaluate target engagement and assess changes in neurodegeneration and disease progression.
Learn More
Closed
, ,

Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD)

Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease, will be referred from the APT Webstudy (above) to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) in-person study. The purpose of TRC-PAD is to find as many people as possible (also called a “cohort”) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer’s dementia. TRC-PAD will help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible. Participants do not have to participate in the TRC-PAD study in order to participate in the online APT Webstudy.
Learn More